Werbung
Attraktive Knock-Outs auf Sanofi SA
Typ Hebel Bid / Ask WKN
Call
5,0 3,26 € / 3,36 €
SW22MM
Typ Hebel Bid / Ask WKN
Put
3,1 2,67 € / 2,67 €
SW17B9
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Sanofi SA

Sanofi Aktie

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF Branche:  Pharmazeutika Land:  Frankreich
82,205 €
+0,55 €
+0,67%
23.12.25
Depot/Watchlist
Marktkapitalisierung *
102,38 Mrd. €
Streubesitz
43,71%
KGV
21,07
Dividende
3,92 €
Dividendenrendite
4,80%
neu: Nachhaltigkeits-Score
68 %
Index-Zuordnung
Euro Stoxx 50
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,51: UJ4G5E
Werbung

Ad-hocs

07:15 Uhr - GlobeNewswire
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
07:00 Uhr - GlobeNewswire
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-​relapsing secondary progressive multiple sclerosis
23.12.25 - GlobeNewswire
Press Release: Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia
23.12.25 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
19.12.25 - GlobeNewswire
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump’s four requests, establishing a ...
17.12.25 - GlobeNewswire
Press release: Availability of the Q4 2025 Aide memoire
Availability of the Q4 2025 Aide memoire
17.12.25 - GlobeNewswire
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi’s commitment to ...
15.12.25 - GlobeNewswire
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
15.12.25 - GlobeNewswire
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Sanofi provides update on tolebrutinib regulatory submission in non-​relapsing secondary progressive multiple sclerosis
11.12.25 - GlobeNewswire
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-​lowering therapy for hemophilia, can offer consistent protection with as ...
04.12.25 - GlobeNewswire
Press Release: Sanofi completes acquisition of Vicebio
Sanofi completes acquisition of Vicebio
25.11.25 - GlobeNewswire
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing ...
14.11.25 - GlobeNewswire
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
07.11.25 - GlobeNewswire
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for ...
28.10.25 - GlobeNewswire
Press release: Sanofi successfully prices USD 3 billion of bond issue
Sanofi successfully prices USD 3 billion of bond issue
24.10.25 - GlobeNewswire
Press release: Q3: continued sales and earnings progress
22.10.25 - GlobeNewswire
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-...
20.10.25 - GlobeNewswire
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be ...
20.10.25 - GlobeNewswire
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-​dose
17.10.25 - GlobeNewswire
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

Newssuche

Videos

newspaper
16.12.25 +1,32%
Technical Trading: DAX Setup mit Kurzfrist Trade
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »